Summit Global Investments Purchases Shares of 19,259 SPDR S&P Biotech ETF (NYSEARCA:XBI)

Summit Global Investments purchased a new stake in SPDR S&P Biotech ETF (NYSEARCA:XBI) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 19,259 shares of the exchange traded fund’s stock, valued at approximately $1,734,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in XBI. Howard Capital Management Group LLC boosted its position in SPDR S&P Biotech ETF by 2.6% in the third quarter. Howard Capital Management Group LLC now owns 248,114 shares of the exchange traded fund’s stock valued at $24,514,000 after buying an additional 6,188 shares in the last quarter. Nwam LLC acquired a new position in SPDR S&P Biotech ETF in the third quarter valued at about $1,475,000. Clal Insurance Enterprises Holdings Ltd acquired a new position in SPDR S&P Biotech ETF in the third quarter valued at about $141,284,000. Great Valley Advisor Group Inc. boosted its position in SPDR S&P Biotech ETF by 28.0% in the third quarter. Great Valley Advisor Group Inc. now owns 3,414 shares of the exchange traded fund’s stock valued at $337,000 after buying an additional 746 shares in the last quarter. Finally, Kingsview Wealth Management LLC boosted its position in SPDR S&P Biotech ETF by 8.2% in the third quarter. Kingsview Wealth Management LLC now owns 3,962 shares of the exchange traded fund’s stock valued at $391,000 after buying an additional 299 shares in the last quarter.

SPDR S&P Biotech ETF Trading Up 0.6 %

Shares of XBI stock opened at $87.12 on Friday. SPDR S&P Biotech ETF has a 1 year low of $81.14 and a 1 year high of $105.47. The firm’s 50 day moving average is $89.59 and its 200-day moving average is $94.35. The firm has a market capitalization of $5.65 billion, a price-to-earnings ratio of 11.47 and a beta of 0.99.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.